• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Mueller C Compher C Ellen DM


    5. Mueller C, Compher C, Ellen DM, et al. A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and intervention in adults. JPEN J Parenter Enteral Nutr 2011; 35:16–24.
    6. Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. Br J Nutr 2004; 92:799–808.
    8. Ferguson M, Capra S, Bauer J, et al. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition 1999; 15:458– 64.
    9. Kruizenga HM, Seidell JC, de Vet HC, et al. Development and validation of a hospital screening tool for malnutrition: the short nutritional assessment questionnaire (SNAQ). Clin Nutr 2005; 24:75–82.
    11. Zhuang CL, Huang DD, Pang WY, et al. Sarcopenia Dihexa (PNB-0408) an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer: Analysis from a Large-Scale Cohort. Medicine (Baltimore) 2016; 95:e3164.
    12. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
    13. Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017; 36:49–64.
    14. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups
    (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”.
    15. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10:90–9.
    17. Ní Bhuachalla ÉB, Daly LE, Power DG, et al. Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition? J Cachexia Sarcopenia Muscle 2018; 9:295–305.
    18. Blauwhoff-Buskermolen S, Langius JAE, Becker A, et al. The influence of different muscle mass measurements on the diagnosis of cancer cachexia. J Cachexia Sarcopenia Muscle 2017; 8:615–22.
    19. von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle 2016; 7:507–9.
    21. Aapro M, Arends J, Bozzetti F, et al. Early recognition of malnutrition and
    cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 2014; 25:1492–9.
    24. Solheim TS, Laird BJA, Balstad TR ,et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 2017; 8:778–88.
    Fig. 1 Classification of malnutrition risk based on the MUST, NRS-2002, MST, and SNAQ tools.
    Table 1. The patients’ demographic characteristics
    All patients
    Values are shown as number (%) unless otherwise indicated.
    IQR, interquartile range; BMI, body mass index; SD, standard deviation; TNM, tumor node metastasis.
    a Undifferentiated carcinomas include poorly differentiated adenocarcinomas, signet ring cell carcinomas, and mucinous carcinomas.
    b Differentiated carcinomas include well or moderately differentiated, tubular, or papillary adenocarcinomas.
    Table 2. Cross tabulation of the results for nutritional risk screening and cachexia classification
    Score ≥1 (at risk of malnutrition)
    Score 0 (not at risk of malnutrition)
    Score ≥3 (at risk of malnutrition)
    Score <3 (not at risk of malnutrition)